article
<h3>Background</h3> The genetic complexity of Plasmodium falciparum is a contributory factor to the emergence of drug-resistant parasites. WHO recommends intermittent preventive treatment of malaria in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) to reduce the deleterious effects of maternal and neonatal malaria in high transmission settings. However, asymptomatic malaria still persists in areas of endemicity despite IPTp-SP regimen. The study evaluated the allelic profiles of Plasmodium falciparum merozoite surface proteins (Pfmsp-1, Pfmsp-2), glutamate-rich protein (Pfglurp) and multidrug resistance-1 gene (Pfmdr-1) in pregnant women on IPTp-SP regimen from southwest Nigeria. <h3>Methods</h3> 100 PCR-confirmed Plasmodium falciparum isolates, comprising visit 1 (V1) (n = 52), Delivery (n = 31) and Cord blood (n = 17) were randomly selected from EDCTP2 funded study (Trial no. 98867 IPTp-SP resistance in Nigeria TMA 2015 CDF – 973). Genomic DNA was genotyped using nested PCR. The Pfmdr-1 gene was further evaluated using restriction fragment length polymorphism (RLFP) at codon 86 with Apo1 restriction-digestion enzyme. Allelic frequencies, proportions and multiplicity of infection was calculated. Statistical significance was considered at p ≤ 0.05. <h3>Results</h3> Isolates from V1 confers 21.2% (Pfmsp-1), 32.7% (Pfmsp-2) and 9.6% (Pfglurp) distinct alleles, while delivery samples had 45.2% (Pfmsp-1), 32.3% (Pfmsp-2) and 6.5% (Pfglurp) allelic types. Cord isolates recorded the highest alleles; 70.6% (Pfmsp-1), 58.0% (Pfmsp-2) and 5.9% (Pfglurp). The MOI for V1 was 2.7, 2.1 and 1.1 for Pfmsp-1, Pfmsp-2 and Pfglurp. Delivery and cord isolates recorded 3.2, 1.9 and 2.7, 1.9 for Pfmsp-1 and Pfmsp-2 respectively; but had monoclonal Pfglurp alleles. The Pfmdr-1 wild/mutant allelic combination (N86Y) was present in 11.8% (V1), 61.3% (Delivery) and 58.8% (Cord blood) p ≤ 0.05. Single point mutation (86Y) was only present in 5.9% cord isolates. <h3>Conclusion</h3> Antigenic falciparum strains with N86Y Pfmdr-1 mutations may limit the efficacy of intermittent sulfadoxine-pyrimethamine prophylaxis of malaria during pregnancy in southwest Nigeria.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1136/bmjgh-2023-edc.130
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.